{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:31:45Z","timestamp":1794486705995,"version":"4.9.1"},"reference-count":61,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2023,9,10]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Microarray patches (MAPs) deliver vaccines to the epidermis and the upper dermis, where abundant immune cells reside. There are several potential benefits to using MAPs, including reduced sharps risk, thermostability, no need for reconstitution, tolerability and self-administration. We aimed to explore and evaluate the immunogenicity, safety, usability and acceptability of MAPs for vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched CINAHL, Cochrane Library, Ovid Embase, Ovid MEDLINE and Web of Science from inception to January 2023. Eligibility criteria included all research studies in any language, which examined microarrays or microneedles intended or used for vaccination and explored immunogenicity, safety, usability or acceptability in their findings. Two reviewers conducted title and abstract screening, full-text reviewing and data extraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two studies were included (quantitative=15, qualitative=2 and mixed methods=5). The risk of bias was mostly low, with two studies at high risk of bias. Four clinical trials were included, three using influenza antigens and one with Japanese encephalitis delivered by MAP. A meta-analysis indicated similar or higher immunogenicity in influenza MAPs compared with needle and syringe (N&amp;S) (standardised mean difference=10.80, 95% CI: 3.51 to 18.08, p&lt;0.00001). There were no significant differences in immune cell function between MAPs and N&amp;S. No serious adverse events were reported in MAPs. Erythema was more common after MAP application than N&amp;S but was brief and well tolerated. Lower pain scores were usually reported after MAP application than N&amp;S. Most studies found MAPs easy to use and highly acceptable among healthcare professionals, laypeople and parents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MAPs for vaccination were safe and well tolerated and evoked similar or enhanced immunogenicity than N&amp;S, but further research is needed. Vaccine uptake may be increased using MAPs due to less pain, enhanced thermostability, layperson and self-administration. MAPs could benefit at-risk groups and low and middle-income countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42022323026.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2023-012247","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T13:05:25Z","timestamp":1697115925000},"page":"e012247","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-6681","authenticated-orcid":false,"given":"Matthew N","family":"Berger","sequence":"first","affiliation":[{"name":"Specialty of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales, Australia"},{"name":"Centre for Population Health, Western Sydney Local Health District, North Parramatta, New South Wales, Australia"},{"name":"Sydney Infectious Diseases Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-8615","authenticated-orcid":false,"given":"Ellen S","family":"Mowbray","sequence":"additional","affiliation":[{"name":"Specialty of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-2998","authenticated-orcid":false,"given":"Marian W A","family":"Farag","sequence":"additional","affiliation":[{"name":"Hillarys Plaza Medical Centre, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5209-7989","authenticated-orcid":false,"given":"Erin","family":"Mathieu","sequence":"additional","affiliation":[{"name":"School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-3285","authenticated-orcid":false,"given":"Cristyn","family":"Davies","sequence":"additional","affiliation":[{"name":"Specialty of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales, Australia"},{"name":"Sydney Infectious Diseases Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6699-5026","authenticated-orcid":false,"given":"Claire","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre for Population Health, Western Sydney Local Health District, North Parramatta, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-7452","authenticated-orcid":false,"given":"Robert","family":"Booy","sequence":"additional","affiliation":[{"name":"Sydney Infectious Diseases Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5363-2015","authenticated-orcid":false,"given":"Angus H","family":"Forster","sequence":"additional","affiliation":[{"name":"Vaxxas Pty Ltd, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-9792","authenticated-orcid":false,"given":"S Rachel","family":"Skinner","sequence":"additional","affiliation":[{"name":"Specialty of Child and Adolescent Health, Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales, Australia"},{"name":"Sydney Infectious Diseases Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Kids Research, The Children\u2019s Hospital at Westmead, Sydney Children's Hospitals Network, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"2025073013312271000_8.10.e012247.1","unstructured":"World Health Organization, United Nations Children\u2019s Fund (UNICEF) . Measles-rubella microarray patch (MR\u2013MAP) target product profile. Geneva: World Health Organization, 2020. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/330394"},{"key":"2025073013312271000_8.10.e012247.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.03.035"},{"key":"2025073013312271000_8.10.e012247.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.10.007"},{"key":"2025073013312271000_8.10.e012247.4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.addr.2021.01.022","article-title":"Microarray patches enable the development of skin-targeted vaccines against COVID-19","volume":"171","author":"Korkmaz","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"2025073013312271000_8.10.e012247.5","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.3390\/molecules26195912","article-title":"Advances of Microneedles in BIOMEDICAL applications","volume":"26","author":"Xu","year":"2021","journal-title":"Molecules"},{"key":"2025073013312271000_8.10.e012247.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.04.005"},{"key":"2025073013312271000_8.10.e012247.7","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2666-5247(21)00269-X","article-title":"Safety and dose-sparing effect of Japanese encephalitis vaccine administered by Microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial","volume":"3","author":"Iwata","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025073013312271000_8.10.e012247.8","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2014.01.076","article-title":"Microneedle patches: usability and acceptability for self-vaccination against influenza","volume":"32","author":"Norman","year":"2014","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/pharmaceutics12111113","article-title":"The current status of clinical research involving Microneedles: A systematic review","volume":"12","author":"Jeong","year":"2020","journal-title":"Pharmaceutics"},{"key":"2025073013312271000_8.10.e012247.10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/21645515.2020.1767997","article-title":"Progress in Microneedle array patch (MAP) for vaccine delivery","volume":"17","author":"Nguyen","year":"2021","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"2025073013312271000_8.10.e012247.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003024","article-title":"Safety, tolerability, and Immunogenicity of influenza vaccination with a high-density Microarray patch: results from a randomized, controlled phase I clinical trial","volume":"17","author":"Forster","year":"2020","journal-title":"PLoS Med"},{"key":"2025073013312271000_8.10.e012247.12","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1016\/j.vaccine.2018.05.053","article-title":"Safety, tolerability, acceptability and Immunogenicity of an influenza vaccine delivered to human skin by a novel high-density Microprojection array patch (NanopatchTM)","volume":"36","author":"Fernando","year":"2018","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30575-5"},{"key":"2025073013312271000_8.10.e012247.14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biomaterials.2015.04.007","article-title":"Clinical study and stability assessment of a novel Transcutaneous influenza vaccination using a dissolving Microneedle patch","volume":"57","author":"Hirobe","year":"2015","journal-title":"Biomaterials"},{"key":"2025073013312271000_8.10.e012247.15","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1016\/j.vaccine.2017.10.021","article-title":"Safety, acceptability and tolerability of uncoated and Excipient-coated high density Silicon micro-projection array patches in human subjects","volume":"35","author":"Griffin","year":"2017","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.16","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1007\/s11095-013-1092-6","article-title":"Development and clinical study of a self-dissolving Microneedle patch for Transcutaneous immunization device","volume":"30","author":"Hirobe","year":"2013","journal-title":"Pharm Res"},{"key":"2025073013312271000_8.10.e012247.17","unstructured":"World Health Organization . Vaccine equity, Available: https:\/\/www.who.int\/campaigns\/vaccine-equity"},{"key":"2025073013312271000_8.10.e012247.18","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1016\/j.vaccine.2021.08.016","article-title":"Micro array patch (MAP) for the delivery of Thermostable vaccines in Australia: a cost\/benefit analysis","volume":"39","author":"Bozorgi","year":"2021","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169030","article-title":"Potential cost-effectiveness of an influenza vaccination program offering Microneedle patch for vaccine delivery in children","volume":"11","author":"Wong","year":"2016","journal-title":"PLoS ONE"},{"key":"2025073013312271000_8.10.e012247.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000394","article-title":"Evaluating the potential cost-effectiveness of Microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: a Modelling study","volume":"2","author":"Seaman","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2025073013312271000_8.10.e012247.21","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9040320","article-title":"Dissolvable Microneedle patches to enable increased access to vaccines against SARS-Cov-2 and future pandemic outbreaks","volume":"9","author":"O\u2019Shea","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025073013312271000_8.10.e012247.22","unstructured":"UNICEF . Vaccine microarray patches (VMAPs), Available: https:\/\/www.unicef.org\/innovation\/vaccine-microarray-patches-vmaps"},{"key":"2025073013312271000_8.10.e012247.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025073013312271000_8.10.e012247.24","unstructured":"Berger MN , Mowbray ES , Farag MWA , et al . Immunogenicity, safety, usability, and acceptability of microarray patches for vaccination: a systematic review 2022, Available: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=323026"},{"key":"2025073013312271000_8.10.e012247.25","unstructured":"Australian Technical Advisory Group on Immunisation (ATAGI) . Australian immunisation handbook. Canberra: Australian Government Department of Health and Aged Care, 2022. Available: https:\/\/immunisationhandbook.health.gov.au\/"},{"key":"2025073013312271000_8.10.e012247.26","unstructured":"Therapeutic Goods Administration . Essential principles checklist (medical devices). 2021. Available: https:\/\/www.tga.gov.au\/resources\/resource\/forms\/essential-principles-checklist-medical-devices"},{"key":"2025073013312271000_8.10.e012247.27","unstructured":"International Organization for Standards . ISO 9241-11:2018(en) Ergonomics of human-system interaction \u2014 Part 11: usability: definitions and concepts 2018, Available: https:\/\/www.iso.org\/obp\/ui\/#iso:std:iso:9241:-11:ed-2:v1:en"},{"issue":"0 1","key":"2025073013312271000_8.10.e012247.28","first-page":"S69","article-title":"Qualitative methods to ensure acceptability of behavioral and social interventions to the target population","volume":"71 Suppl 1","author":"Ayala","year":"2011","journal-title":"J Public Health Dent"},{"key":"2025073013312271000_8.10.e012247.29","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1016\/j.vaccine.2021.06.074","article-title":"HPV vaccine acceptance in West Africa: a systematic literature review","volume":"39","author":"Wilson","year":"2021","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.30","unstructured":"National Heart, Lung, and Blood Institute . Study quality assessment tools. 2021. Available: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"2025073013312271000_8.10.e012247.31","unstructured":"Critical Appraisal Skills Programme . CASP qualitative studies checklist 2018, Available: https:\/\/casp-uk.net\/casp-tools-checklists\/"},{"key":"2025073013312271000_8.10.e012247.32","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025073013312271000_8.10.e012247.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025073013312271000_8.10.e012247.34","unstructured":"Cochrane . Review manager (Revman). 2020. Available: https:\/\/training.cochrane.org\/online-learning\/core-software\/revman"},{"key":"2025073013312271000_8.10.e012247.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (swim) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2025073013312271000_8.10.e012247.36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-8-45","article-title":"Methods for the thematic synthesis of qualitative research in systematic reviews","volume":"8","author":"Thomas","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"2025073013312271000_8.10.e012247.37","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1021\/acsnano.1c10718","article-title":"Smart mushroom-inspired Imprintable and lightly detachable (MILD) Microneedle patterns for effective COVID-19 vaccination and decentralized information storage","volume":"16","author":"Li","year":"2022","journal-title":"ACS Nano"},{"key":"2025073013312271000_8.10.e012247.38","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s11095-014-1301-y","article-title":"Hydrogel-forming Microneedle arrays can be effectively inserted in skin by self-application: a pilot study centred on pharmacist intervention and a patient information leaflet","volume":"31","author":"Donnelly","year":"2014","journal-title":"Pharm Res"},{"key":"2025073013312271000_8.10.e012247.39","doi-asserted-by":"crossref","unstructured":"Iredahl F , Muller DA , Tog\u00f6 T , et al . n.d. Local response and barrier recovery in elderly skin following the application of high-density Microarray patches. Vaccines;10:583. doi:10.3390\/vaccines10040583 Available: https:\/\/doi.org\/10.3390\/vaccines10040583","DOI":"10.3390\/vaccines10040583"},{"key":"2025073013312271000_8.10.e012247.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75169-4","article-title":"Innate local response and tissue recovery following application of high density Microarray patches to human skin","volume":"10","author":"Muller","year":"2020","journal-title":"Sci Rep"},{"key":"2025073013312271000_8.10.e012247.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255282","article-title":"Cellular responses at the application site of a high-density Microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial","volume":"16","author":"Depelsenaire","year":"2021","journal-title":"PLoS One"},{"key":"2025073013312271000_8.10.e012247.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00353-0","article-title":"Immunologic mechanisms of seasonal influenza vaccination administered by Microneedle patch from a randomized phase I trial","volume":"6","author":"Rouphael","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2025073013312271000_8.10.e012247.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.02.040"},{"key":"2025073013312271000_8.10.e012247.44","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1016\/j.vaccine.2020.07.064","article-title":"Acceptability of an Inactivated influenza vaccine delivered by Microneedle patch: results from a phase I clinical trial of safety, Reactogenicity, and Immunogenicity","volume":"38","author":"Frew","year":"2020","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.45","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2018863","article-title":"Usability, acceptability, and feasibility of a high-density Microarray patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings","volume":"18","author":"Davies","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2025073013312271000_8.10.e012247.46","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.vaccine.2019.02.079","article-title":"End-user acceptability study of the Nanopatch; a Microarray patch (MAP) for child immunization in low and middle-income countries","volume":"37","author":"Guillermet","year":"2019","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.47","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1016\/j.vaccine.2015.03.062","article-title":"Opportunities and challenges in delivering influenza vaccine by Microneedle patch","volume":"33","author":"Jacoby","year":"2015","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11095-010-0101-2","article-title":"Microneedles in clinical practice--an exploratory study into the opinions of Healthcare professionals and the public","volume":"28","author":"Birchall","year":"2011","journal-title":"Pharm Res"},{"key":"2025073013312271000_8.10.e012247.49","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1016\/j.vaccine.2017.07.083","article-title":"Acceptability of Microneedle-patch vaccines: A qualitative analysis of the opinions of parents","volume":"35","author":"Marshall","year":"2017","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.50","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.idh.2022.09.014","article-title":"30. use of Microarray patches for vaccination in older adults during a pandemic","volume":"27","author":"Berger","year":"2022","journal-title":"Infection, Disease & Health"},{"key":"2025073013312271000_8.10.e012247.51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7339.690"},{"key":"2025073013312271000_8.10.e012247.52","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06493-5","article-title":"Study protocol for a phase 1\/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and Immunogenicity of a measles and rubella vaccine delivered by a Microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-Na\u00efve infants (9 to 10 months) in the Gambia","volume":"23","author":"Adigweme","year":"2022","journal-title":"Trials"},{"key":"2025073013312271000_8.10.e012247.53","unstructured":"Australian New Zealand Clinical Trials Registry . Phase I clinical study with high-density microarray patches (HD-MAPs) coated with live attenuated measles and rubella vaccine (MR) in healthy adult volunteers 2022, Available: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=381749&isReview=true"},{"key":"2025073013312271000_8.10.e012247.54","unstructured":"Australian New Zealand Clinical Trials Registry . Phase I clinical study to evaluate the safety and tolerability of SARS-CoV-2 spike protein (HexaPro) delivered intradermally by a high-density microarray patch (HD-MAP), in healthy adults aged 18 to 50 years. 2022, Available: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=383935&isReview=true"},{"key":"2025073013312271000_8.10.e012247.55","unstructured":"National Library of Medicine . Establishing Immunogenicity and safety of needle-free intradermal delivery of mRNA COVID-19 vaccine (MILESTONE). 2022. Available: https:\/\/clinicaltrials.gov\/study\/NCT05315362?intr=Microneedle%20patch&rank=10"},{"key":"2025073013312271000_8.10.e012247.56","unstructured":"Australian New Zealand Clinical Trials Registry . Safety, performance, and acceptability of intradermal application of an excipient-coated High Density Micro-Array Patch (HD-MAP) delivery system: Study in children and their parents\/guardians 2023, Available: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=384456&isReview=true"},{"key":"2025073013312271000_8.10.e012247.57","doi-asserted-by":"crossref","DOI":"10.1177\/2377960818759442","article-title":"Fear of injections and needle Phobia among children and adolescents: an overview of psychological, behavioral, and Contextual factors","volume":"4","author":"Orenius","year":"2018","journal-title":"SAGE Open Nurs"},{"key":"2025073013312271000_8.10.e012247.58","doi-asserted-by":"publisher","DOI":"10.1111\/jan.13818"},{"key":"2025073013312271000_8.10.e012247.59","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0144-x"},{"key":"2025073013312271000_8.10.e012247.60","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1016\/j.vaccine.2015.02.076","article-title":"An economic model assessing the value of Microneedle patch delivery of the seasonal influenza vaccine","volume":"33","author":"Lee","year":"2015","journal-title":"Vaccine"},{"key":"2025073013312271000_8.10.e012247.61","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2050123","article-title":"Opportunities and challenges for Commercializing Microarray patches for vaccination from a MAP developer\u2019s perspective","volume":"18","author":"Forster","year":"2022","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2023-012247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:31:34Z","timestamp":1753907494000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2023-012247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,12]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjgh-2023-012247"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2023-012247","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}